Eli Lilly's Strategic Growth Amid Medicare Expansions
Discover how Eli Lilly's strategic alignment with Medicare expands its growth in obesity treatments while adapting to market dynamics. Key insights included.
Medicare Expands Coverage for GLP-1 Medications for Obesity
Medicare introduces coverage for GLP-1 medications targeting obesity, enhancing access for beneficiaries to affordable treatment options.
Eli Lilly and Boehringer Ingelheim Adjust Investment Strategies in Germany
Eli Lilly and Boehringer Ingelheim cut investment in Germany due to proposed healthcare spending reductions, impacting the pharmaceutical industry and insurance subsidies.
Trump's Stock Moves in Eli Lilly: Ethics and Healthcare Implications
Discover Trump's stock dealings in Eli Lilly amidst healthcare regulation changes, exploring the interplay of ethics and the pharmaceutical industry.
Eli Lilly's Mounjaro Added to China's National Health Insurance Program
Eli Lilly's diabetes drug Mounjaro is set to be included in China's national health insurance reimbursement list, boosting accessibility but with potential revenue impact from pricing adjustments.
Novo Nordisk Seeks FDA Approval for Oral Anti-Obesity Drug Amid GLP-1 Market Competition
Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.